Federal regulators have approved a new type of seasonal flu vaccine with a booster in it that's intended to trigger a stronger immunity response in the elderly.
What they fail to mention is that this newfangled flu vaccine could cause chronic health problems far worse than the flu itself.
Fluad, made by Novartis Vaccines and Diagnostics Limited, contains an adjuvant called MF59, which is a substance that boosts or directs the immune response of a vaccinated individual. The adjuvant in Fluad uses an oil-in-water emulsion of squalene oil, a naturally-occurring substance produced by humans, animals, and plants that is highly purified in vaccines. 
Experts aren't sure why, but when MF59 is mixed with vaccines, it increases the number of immune cells that are stimulated.
The new vaccine contains 3 strains of influenza: two subtype A and the other type B. Fluad is intended specifically for people aged 65 and older.
"Immunizing individuals in this age group is especially important because they bear the greatest burden of severe influenza disease and account for the majority of influenza-related hospitalizations and deaths," said Dr. Karen Midthun of the U.S. Food and Drug Administration (FDA).